 Bull World Health Organ 2017;95:629–638 | doi: http://dx.doi.org/10.2471/BLT.16.178475
Research
629
Estimated economic impact of vaccinations in 73 low- and middle-
income countries, 2001–2020
Sachiko Ozawa,a Samantha Clark,b Allison Portnoy,c Simrun Grewal,d Meghan L Stack,e Anushua Sinha,f 
Andrew Mirelman,g Heather Franklin,f Ingrid K Friberg,h Yvonne Tam,b Neff Walker,b Andrew Clark,i 
Matthew Ferrari,j Chutima Suraratdecha,k Steven Sweet,l Sue J Goldie,l Tini Garske,m Michelle Li,n 
Peter M Hansen,o Hope L Johnsonn & Damian Walkerp
Introduction
While vaccination is generally regarded to be one of the most 
cost-effective interventions in public health, the introduction 
and sustained use of any new vaccine needs to be supported by 
decision-makers who appreciate the full potential economic 
benefits that result.1–5 This paper focuses on the economic 
benefits of the vaccinations given, against 10 diseases, in 73 
low- and middle-income countries supported by Gavi, the 
Vaccine Alliance, since Gavi’s establishment in 2001.
In 2011, disease modelling experts were convened, by 
Gavi and the Bill & Melinda Gates Foundation, to estimate 
the global impact of immunization beyond the original 
Expanded Programme on Immunization – based on the 
latest forecasts of vaccine demand and estimates of disease 
burden. In 2013, these experts developed health impact 
models to estimate the numbers of cases of illness, deaths and 
disability-adjusted life-years (DALYs) averted as the result of 
vaccination against 10 diseases in 73 low- or middle-income 
countries.6,7 Recently, we built on the output from these 
models by estimating the corresponding economic impact. 
To reflect the full impact of vaccinations in low-and middle-
income countries, we captured not only the traditional costs 
of illness – e.g. productivity losses averted and treatment 
costs saved – but also projected the long-term economic and 
social benefits of vaccinations.2
Objective To estimate the economic impact likely to be achieved by efforts to vaccinate against 10 vaccine-preventable diseases between 
2001 and 2020 in 73 low- and middle-income countries largely supported by Gavi, the Vaccine Alliance.
Methods We used health impact models to estimate the economic impact of achieving forecasted coverages for vaccination against 
Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, 
rotavirus, rubella, Streptococcus pneumoniae and yellow fever. In comparison with no vaccination, we modelled the costs – expressed in 
2010 United States dollars (US$) – of averted treatment, transportation costs, productivity losses of caregivers and productivity losses due 
to disability and death. We used the value-of-a-life-year method to estimate the broader economic and social value of living longer, in 
better health, as a result of immunization.
Findings We estimated that, in the 73 countries, vaccinations given between 2001 and 2020 will avert over 20 million deaths and save 
US$ 350 billion in cost of illness. The deaths and disability prevented by vaccinations given during the two decades will result in estimated 
lifelong productivity gains totalling US$ 330 billion and US$ 9 billion, respectively. Over the lifetimes of the vaccinated cohorts, the same 
vaccinations will save an estimated US$ 5 billion in treatment costs. The broader economic and social value of these vaccinations is estimated 
at US$ 820 billion.
Conclusion By preventing significant costs and potentially increasing economic productivity among some of the world’s poorest countries, 
the impact of immunization goes well beyond health.
a Division of Practice Advancement and Clinical Education, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, CB # 7574, Beard Hall 115H, 
Chapel Hill, North Carolina, 27599, United States of America (USA).
b Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.
c Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston, USA.
d Department of Pharmacy, University of Washington, Seattle, USA.
e Independent Consultant, Denver, USA.
f Department of Preventive Medicine and Community Health, Rutgers New Jersey Medical School, Newark, USA.
g Centre for Health Economics, University of York, York, England.
h Department of Health Services, Norwegian Institute of Public Health, Oslo, Norway.
i Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, England.
j Center for Infectious Disease Dynamics, The Pennsylvania State University, University Park, USA.
k Independent Consultant, Vienna, USA.
l Center for Health Decision Science, Harvard TH Chan School of Public Health, Boston, USA.
m MRC Centre for Outbreak Analysis and Modelling, Imperial College London, London, England.
n Gavi, the Vaccine Alliance, Geneva, Switzerland.
o The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland.
p Bill & Melinda Gates Foundation, Seattle, USA.
Correspondence to Sachiko Ozawa (email: ozawa@unc.edu).
(Submitted: 27 May 2016 – Revised version received: 31 May 2017 – Accepted: 2 June 2017 – Published online: 27 June 2017 )
 Bull World Health Organ 2017;95:629–638| doi: http://dx.doi.org/10.2471/BLT.16.178475
630
Research
Economic impact of vaccination against 10 diseases
Sachiko Ozawa et al.
Methods
Cost of illness
Since 2001, 73 countries with per-capita 
gross national incomes in 2003 of no 
more than 1000 United States dollars 
(US$) have received Gavi support. Our 
analysis was based on data for these 
73 low- or middle-income countries 
(Box 1). We estimated the health and 
economic impact of vaccination against 
10 vaccine-preventable diseases: Hae-
mophilus influenzae type b, hepatitis 
B, human papillomavirus, Japanese 
encephalitis, measles, Neisseria menin-
gitidis serogroup A, rotavirus, rubella, 
Streptococcus pneumoniae and yellow 
fever. Table 1 presents the relevant 
health outcomes, permanent disabilities 
and vaccines that we included in our 
models. While all of our study vaccines 
are delivered via routine immunization, 
supplementary immunization activities 
also occur for Japanese encephalitis, 
measles, N. meningitidis serogroup A, 
rubella and yellow fever. Our estimates 
of the numbers of deaths, cases and 
DALYs averted as the result of vaccina-
tion were developed from health impact 
models, as previously described.6,7 We 
used data on immunization coverages 
published by the World Health Orga-
nization (WHO) and United Nations 
Children’s Fund to estimate annual vac-
cine coverages for each study country 
for the period 2001–20128 and version 9 
of Gavi’s strategic demand forecast to 
estimate the corresponding probable 
coverages for the period 2013–2020.9
Using the cost of illness approach10 
from a societal perspective, we estimated 
treatment costs and productivity losses 
averted by vaccination based on the 
estimated numbers of cases, deaths 
and disabilities averted.11 For each of 
the 10 diseases studied, we constructed 
decision tree models to capture both the 
short- and long-term averted costs of 
illness. These costs were broken down 
into five categories: (i) averted treatment 
costs; (ii) averted transportation costs 
for seeking care; (iii) averted reduc-
tion in caregivers’ economic output; 
(iv) averted loss of productivity due to 
premature death; and (v) averted loss of 
survivors’ productivity due to disability. 
All estimates of the averted cost of illness 
were discounted at 3% and are expressed 
in 2010 US$. We present separate results 
for the 20 years following Gavi’s estab-
lishment – i.e. 2001–2020 – and the cur-
rent so-called Decade of Vaccines – i.e. 
2011–2020.
In estimating the immunization-
attributable averted costs of treatment, 
transportation and lost caregiver pro-
ductivity, we used the country-specific 
estimated proportions of children for 
whom care was sought12 as well as data 
Box 1. Countries included in the analysis on the estimated economic impact of 
vaccinations, 2001–2020
Afghanistan, Angola, Armenia, Azerbaijan, Bangladesh, Benin, Bhutan, Bolivia (Plurinational 
State of), Burkina Faso, Burundi, Cambodia, Cameroon, Central African Republic, Chad, Comoros, 
Congo, Côte d’Ivoire, Cuba, Democratic People’s Republic of Korea, Democratic Republic of the 
Congo, Djibouti, Eritrea, Ethiopia, Gambia, Georgia, Ghana, Guinea, Guinea-Bissau, Guyana, 
Haiti, Honduras, India, Indonesia, Kenya, Kiribati, Kyrgyzstan, Lao People’s Democratic Republic, 
Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mongolia, Mozambique, Myanmar, Nepal, 
Nicaragua, Niger, Nigeria, Pakistan, Papua New Guinea, Republic of Moldova, Rwanda, Sao Tome 
and Principe, Senegal, Sierra Leone, Solomon Islands, Somalia, South Sudan, Sri Lanka, Sudan, 
Tajikistan, Timor-Leste, Togo, Uganda, Ukraine, United Republic of Tanzania, Uzbekistan, Viet 
Nam, Yemen, Zambia and Zimbabwe.
Table 1. Model parameters for 10 vaccine-preventable diseases 
Pathogen
Vaccines
Target disease
Death and disabilities 
adverted
Haemophilus 
influenzae 
type b
Pentavalent
Meningitis and 
pneumonia
Death, deafness, cognitive 
impairment, motor 
impairment and seizure 
disorder
Hepatitis B
virus
Monovalent, 
tetravalent 
(DTP–HepB) or 
pentavalent (DTP–
HepB–Hib)
Acute/fulminant 
infection, chronic 
infection, hepatocellular 
carcinoma, compensated 
and decompensated 
cirrhosis
Death
Human 
papillomavirus
Recombinant 
quadrivalent or 
bivalent
Cervical cancer
Death
Japanese 
encephalitis
virus
Live attenuated
Japanese encephalitis
Death, neurological 
sequelae/cognitive 
impairment
Measlesa
virus
Live attenuated 
(measles or 
measles–rubella)
Measles
Death, central nervous 
system sequelae
Neisseria 
meningitidis 
serogroup A
Conjugate
Meningitis
Death, deafness, vision 
impairment, motor 
impairment and seizure 
disorder
Rotavirus
Attenuated oral 
rotavirus (RV1 or 
RV5)
Severe and non-severe 
diarrhoea
Death
Rubella
virus
Live attenuated 
(rubella or 
measles–rubella)
Congenital rubella 
syndrome
Death, hearing loss, vision 
loss, cardiac abnormalities 
and central nervous 
system complications
Streptococcus 
pneumoniae
Conjugate (PCV10 
or PCV13)
Meningitis and 
pneumonia
Death, deafness, cognitive 
impairment, motor 
impairment and seizure 
disorder
Yellow fever
virus
Live attenuated 
(17D)
Yellow fever disease
Death
DTP: diphtheria–tetanus–pertussis; HepB: hepatitis B; Hib: Haemophilus influenzae type b; PCV10: 10-valent 
pneumococcal conjugate vaccine; PCV13: 13-valent pneumococcal conjugate vaccine; RV1: Rotarix®; RV5: 
RotaTeq®.
a  For our analysis, we only captured the benefits of second doses of measles vaccine and measles-related 
supplementary immunization activities. We did not estimate the impact of the first doses as they formed a 
standard component of national immunization programmes.
 Bull World Health Organ 2017;95:629–638| doi: http://dx.doi.org/10.2471/BLT.16.178475
631
Research
Economic impact of vaccination against 10 diseases
Sachiko Ozawa et al.
on the duration and rates of hospital 
admission.13–18 Country-specific costs 
of relevant inpatient and outpatient 
care at hospitals and health centres were 
primarily obtained from the WHO’s 
Choosing Interventions that are Cost-
Effective (WHO-CHOICE) project.19 
Costs of medications and diagnostics 
were estimated as proportions of facility 
costs. We assumed that each inpatient 
admission or outpatient visit was as-
sociated with a fixed transportation 
cost – i.e. a country-specific estimated 
mean cost of a return trip to and from 
a health-care facility.20 We also assumed 
that caregivers of sick children lost half 
their daily productivity for an outpatient 
visit and a full day’s productivity for 
each day a child was hospitalized. In 
each study country, a caregiver’s daily 
productivity was assumed to equal the 
daily minimum wage.21
Lost productivity resulting from 
convalescence and long-term disability 
was estimated for cases that could be 
averted by vaccination. To account for 
other causes of mortality that may im-
pact the number of survivors entering 
the workforce, age-specific survival rates 
were applied to the non-fatal cases. The 
total number of productive years lost 
due to disability was estimated using the 
difference between life expectancy and 
mean age at disability onset – incorporat-
ing relevant disability weights. Estimates 
of life expectancy were derived from 
data published by the United Nations’ 
Population Division22 and disability 
weights from the 2010 Global Burden of 
Disease study.23 For each study country, 
we estimated lost productivity resulting 
from disability and premature mortality 
by multiplying the number of produc-
tive life-years lost due to disability or 
premature death by the projected annual 
values for the per-capita gross domestic 
product.24 The values we give for total 
averted long-term productivity losses 
represent the projected economic out-
puts of children whose disability or death 
are – or will be – prevented through 
immunization. Children were assumed 
to begin their economically productive 
lives when they reached an age of 15 
years. Further detail on the key inputs, 
assumptions and data sources used for 
our analysis has been published.7
Economic and social value
We used a second method to capture 
the broader economic and social value 
placed on living longer and healthier 
lives as a result of vaccination. For this, 
we applied a value-of-life approach that 
provides a societal perspective of the 
full benefits of reduced mortality. The 
estimated value of a life-year was based 
on data from two sources: (i) wage risk 
studies that use data on labour markets 
to examine the trade-off between wages 
and risk of mortality while employed; 
and (ii) stated preference studies in 
which individuals are asked how much 
they are willing to pay to avoid certain 
risks of death.25,26 Based on earlier work 
to estimate the annual per-capita value 
of an increase in life expectancy,27–30 we 
assumed that the value of a life-year 
saved in a particular country was 1.6 
times that country’s annual per-capita 
gross domestic product. The economic 
and social value of vaccinations was 
estimated from the number of deaths 
averted due to vaccines, the difference 
between life expectancy and mean age 
of death from each study disease and 
the relevant per-capita gross domestic 
product (GDP).31
Traditional estimates of the value 
of a life-year have focused on estimat-
ing the full benefits of mortality reduc-
tion – with few studies examining the 
impact of corresponding reductions in 
morbidity.28,32 To reflect the benefit of 
averting morbidity, we estimated the 
value of a year lived with disability. As 
in the estimation of years lived with 
disability and years of life lost – both 
used to calculate a DALY – disability 
weights were applied to estimate the 
impact of various disabling conditions 
on an individual’s value of life from the 
age of disease onset to expected age at 
death.22 Disability weights varied from 
0 – representing perfect health – to 1 – 
representing death. A similar approach 
was used in a previous estimation of the 
impact of disability on the value of a life-
year.28 Our estimate of the value of a year 
lived with disability was used to estimate 
the full economic loss associated with 
permanent, long-term disability caused 
by any of the six study diseases that can 
have permanent sequelae – i.e. H. in-
fluenzae type b, Japanese encephalitis, 
measles, N. meningitidis serogroup A, 
rubella and S. pneumoniae.
Sensitivity analysis
Multivariate Monte Carlo simula-
tions, with 10 000 replications, were 
performed to assess the impact on cost 
estimates of uncertainty in the values 
of several key parameters: labour-force 
participation, per-capita GDP, the num-
bers of cases and deaths averted, the 
multiplier – otherwise set at 1.6 – used 
in the estimation of the value of a life-
year, transportation costs and WHO-
CHOICE treatment costs. Cost values 
were sampled from γ distributions to 
represent the right skew of observed 
costing data while non-cost values were 
sampled from β distributions. Lower 
and upper ranges of distributions were 
derived from health impact models or 
published literature. Results from the 
sensitivity analysis were used to con-
struct 90% uncertainty ranges around 
point estimates and generate a tornado 
diagram illustrating the degree to which 
individual parameters influenced the 
final results. The analysis was performed 
using version 6 of the @RISK software 
package (Palisade Corporation, Ithaca, 
United States of America).
Results
Cost of illness
Table 2 presents estimates of the health 
and economic impact, for the period 
of 2001–2020 and the decade of 2011–
2020, of averting 10 vaccine-preventable 
diseases in the 73 countries. According 
to our analyses, use of life-saving vac-
cines will avert an estimated 20 million 
deaths, 500 million cases of illness, 9 
million cases of long-term disability and 
960 million DALYs between 2001 and 
2020. During the Decade of Vaccines, 
introduction and/or increased coverage 
of the modelled vaccines are projected to 
avert over 14 million deaths, 350 million 
cases of illness, 8 million cases of long-
term disability and 700 million DALYs.
By 2020, immunizations since 2001 
will have averted an estimated US$ 350 
billion (uncertainty range: 260–460 bil-
lion) in total costs due to illness. Most 
of these costs – about US$ 250 billion 
(uncertainty range: 190–330 billion) 
– will have been averted since 2011, 
of which about US$ 240 billion (uncer-
tainty range: 180–320 billion) represents 
averted productivity loss caused by 
premature death. Between 2011 and 
2020, US$ 4 billion (uncertainty range: 
3–4 billion) in treatment costs, US$ 350 
million (uncertainty range: 240–490 
million) in transportation costs and 
US$ 730 million (uncertainty range: 
650–790 million) in caregiver produc-
tivity losses could be averted. When we 
estimated the total cost of illness averted 
 Bull World Health Organ 2017;95:629–638| doi: http://dx.doi.org/10.2471/BLT.16.178475
632
Research
Economic impact of vaccination against 10 diseases
Sachiko Ozawa et al.
Table 2. Estimated economic and health benefits of vaccinations against 10 diseases, 73 Gavi-supported low- and middle-income countries, 2001–2020 and 2011–2020
Period, 
pathogen
Mortality and morbidity averteda
DALYs 
averted 
(millions)a
Averted costs of illnessb
Value of 
life-year of 
disability 
averted 
(billions of 
US$)b
Economic 
and social 
value 
(billions of 
US$)b
Deaths 
(thousands)
Cases 
(millions)
Long-term 
disability 
(thousands)c
Acute disease 
hospitalizations 
(millions)
Treatment 
costs 
(millions of 
US$)
Transport 
costs 
(millions of 
US$)
Lost 
caregiver 
wages 
(millions of 
US$)
Productivity 
loss due to 
disability 
(billions of 
US$)c
Productivity 
loss due to 
death (billions 
of US$)
Total 
(billions 
of US$)
2001–2020
HepB
7 200
120
N/A
0.5
210
1 148.8
134.4
25.2
1.3
46.9
49.5
N/A
81.3
Hib
2 700
83
4 900
25
180
1 815.8
94.6
399.9
2.5
58.9
63.7
7.4
180.1
HPV
850
1.1
N/A
1.1
16
6
0.9
N/A
0.9
3.2
4
NA
5
JE
59
0.3
67
0.2
8.4
33.5
0.2
1.6
0.4
2.1
2.5
0.6
4.2
Measles
5 100
210
350
21
310
361.7
168.6
223.7
1.4
139.8
142
3.6
349.4
NmA
470
3.1
380
1.4
23
39.8
1.2
0.2
0.7
7.8
8.6
1.1
13.7
Rotavirus
390
21
N/A
0.7
25
45
17.6
22.8
N/A
8.7
8.8
N/A
25.8
Rubella
280
0.9
270
0.5
26
19
1.3
16
0.6
4.5
5.1
1.5
14.2
Sp
1 700
51
3 200
14
110
773.9
51.3
197.2
1.5
31
33.5
4.3
96.2
YF
1 600
7.8
N/A
5.3
57
336.7
20.6
N/A
0.2
28.9
29.4
N/A
46.2
Total
20 000
500
9 200
70
960
4 580.2
490.8
886.4
9.4
331.8
347.1
18.6
816.1
2011–2020
HepB
4 700
80
N/A
0.3
140
719.2
87
16.1
0.8
28.8
30.4
N/A
50.1
Hib
2 200
72
4 300
22
150
1 542
82.7
347.5
2.2
49.4
53.6
6.4
150.9
HPV
850
1.1
NA
1.1
16
6
1.2
NA
0.9
3.2
4
N/A
5
JE
38
0.2
44
0.1
6.9
21.3
0.2
1.5
0.2
1.3
1.5
0.4
2.7
Measles
2 900
120
200
13
180
223.1
96.7
131.2
0.9
87.1
88.4
2.2
218.2
NmA
440
3
350
1.3
21
38.4
1.2
0.2
0.7
7.5
8.3
1.1
13.1
Rotavirus
390
21
N/A
0.7
25
44.7
17.5
22.6
N/A
8.7
8.8
N/A
25.7
Rubella
260
0.9
250
0.5
24
15
1.2
13
0.5
4
4.5
1.4
12.5
Sp
1 700
51
3 200
14
110
772.8
51.2
196.8
1.5
30.9
33.4
4.3
95.9
YF
940
4.7
N/A
3.2
34
210.6
13.2
N/A
0.1
18.2
18.5
N/A
29.2
Total
14 000
350
8 300
56
700
3 593.1
352.1
728.8
7.7
239
251.4
15.8
603.4
DALY: disability-adjusted life-year; HepB: hepatitis B virus; Hib: Haemophilus influenzae type b; HPV: human papillomavirus; JE: Japanese encephalitis virus; N/A: not applicable; NmA: Neisseria meningitidis serogroup A; Sp: Streptococcus pneumoniae; 
US$: United States dollars; YF: yellow fever virus.
a  Estimates rounded.
b  Expressed in 2010 values.
c  Includes lifelong disabilities following childhood infection with Hib, JE, measles, NmA, rubella or Sp (Table 1).
 Bull World Health Organ 2017;95:629–638| doi: http://dx.doi.org/10.2471/BLT.16.178475
633
Research
Economic impact of vaccination against 10 diseases
Sachiko Ozawa et al.
by vaccination against each of our 
study diseases, it appeared that greater 
costs could be averted, per vaccinated 
individual, through protection against 
H. influenzae type b, S. pneumoniae, 
human papillomavirus and measles than 
protection against any of the other six 
study diseases (Table 3).
Projected introductions of new 
vaccines and supplementary immuni-
zation activities account for US$ 170 
billion – about 66% – of the estimated 
economic benefits of the Decade of Vac-
cines, with the remainder attributable 
to the scale-up in coverage of vaccines 
introduced before 2011. Supplementary 
immunization activities against measles 
represented the largest contributor to 
our estimates of the overall averted costs 
of illness – representing approximately 
US$ 130 billion (uncertainty range: 70–
220 billion), or about 37% of total avert-
ed costs, and US$ 76 billion (uncertainty 
range: 42–133 billion), or about 30% 
of total averted costs, for the periods 
2001–2020 and 2011–2020, respectively. 
The second, third and fourth largest 
drivers of the cost of illness appeared to 
be H. influenzae type b, S. pneumoniae 
and hepatitis B, respectively. Fig. 1 
shows the disease-specific costs of illness 
averted by vaccination, for the periods 
2001–2020 and 2011–2020. Most of 
these averted costs were represented by 
the productivity saved as the result of 
reduced mortality. Of the 73 countries 
included in the analysis, the five with the 
largest birth cohorts – i.e. Bangladesh, 
India, Indonesia, Nigeria and Pakistan – 
together accounted for more than half of 
the estimated total cost of illness averted 
between 2011 and 2020 (available from 
the corresponding author). In terms of 
the estimated total averted costs of ill-
ness per vaccinated individual (available 
from the corresponding author), the 
study countries in the WHO African 
Region came highest, at US$ 71, fol-
lowed by those in the South-East Asia 
(US$ 58), Western Pacific (US$ 56), 
Eastern Mediterranean (US$ 45) and 
European (US$ 33) Regions and then 
the Region of the Americas (US$ 20).
Sensitivity analysis indicated that 
our estimates of the averted costs of 
illness were most sensitive to variation 
in estimates of the numbers of deaths 
averted by vaccination, particularly 
against diseases associated with a high 
disease burden and young age at onset 
– e.g. H. influenzae type b, measles, 
rotavirus and S. pneumoniae (available 
from the corresponding author). Cost 
parameters such as per-capita GDP 
proved to be less influential.
Economic and social value
In terms of their overall broader eco-
nomic and social impact, we estimated 
the vaccinations we investigated to be 
worth approximately US$ 820 billion 
(uncertainty range: 560–1200 billion) 
and US$ 600 billion (uncertainty range: 
420–870 billion) over the periods 
2001–2020 and 2011–2020, respectively. 
About 97% of each of these values was 
represented by the value of averted 
mortality. Averted morbidity contrib-
uted much less – about US$ 19 billion 
(uncertainty range: 16–22 billion) and 
US$ 16 billion (uncertainty range: 14–19 
billion) over the periods 2001–2020 and 
2011–2020, respectively. Over half of the 
estimated economic and social value of 
vaccination in 2001–2020 is attributable 
to vaccinations against H. influenzae 
type b, hepatitis B and S. pneumoniae. 
Fig. 2 presents a year-on-year compari-
son of the estimated economic and social 
values, costs of illness averted and deaths 
averted between 2001 and 2020. The 
annual fluctuations shown are largely a 
result of supplementary immunization 
activities against measles, which are 
scheduled to peak every other year.
Similar to our estimates of the 
averted costs of illness, our broader es-
timates of the economic and social value 
of vaccinations were most sensitive to 
variation in the estimated health impact 
of vaccinations against childhood ill-
nesses with a high disease burden – e.g. 
H. influenzae type b, measles, rotavirus 
and S. pneumoniae.
Discussion
Between 2001 and 2020, according to 
our estimates, immunization against 
10 vaccine-preventable diseases in 73 
low- or middle-income countries will 
avert almost 20 million child deaths and 
save US$ 350 billion in costs of illness. 
More than two-thirds of these benefits 
are expected to accrue from new vaccine 
introductions and increases in immu-
nization coverage during the Decade of 
Vaccines. Between 2001 and 2020 – just 
Table 3. Costs of illness averted as the result of vaccinations against 10 diseases, 73 
Gavi-supported low- and middle-income countries, 2001–2020
Pathogen
Averted costs of illness (2010 US$)
Per vaccinated 
individuala
Per care-seeking case 
avertedb
Per death avertedc
Hepatitis B virus 
61
12
7 000
Haemophilus 
influenzae type b 
105
48
22 000
Human 
papillomavirus 
102
7
4 000
Japanese 
encephalitis virus
9
200
35 000
Measles virus
85
7
27 000
Neisseria 
meningitidis 
serogroup A
25
31
17 000
Rotavirus
37
9
23 000
Rubella virus
5
71
16 000
Streptococcus 
pneumoniae 
122
38
19 000
Yellow fever virus 
72
10
19 000
US$: United States dollars.
a  The averted costs are both short-term – i.e. those incurred immediately at disease onset as the result of 
treatment, transportation or lost caregiver wages – and long-term – i.e. those associated with productivity 
lost, as a result of disease and/or disability, over the lifetime of the affected individual. This was calculated 
by dividing the total cost of illness by the number of individuals who received the recommended course 
of vaccine doses against that antigen.
b  These estimates are based only on averted short-term costs of illness. This estimates the averted cost 
of treatment, transportation and lost caretaker wages divided by the number of individuals with each 
vaccine-preventable disease who likely sought health-care treatment.
c  These estimates are based on data from care-seeking cases who subsequently died and exclude 
individuals with productivity loss due to disability.
 Bull World Health Organ 2017;95:629–638| doi: http://dx.doi.org/10.2471/BLT.16.178475
634
Research
Economic impact of vaccination against 10 diseases
Sachiko Ozawa et al.
Fig. 1. Costs of illness averted as the result of vaccinations against 10 diseases, 73 Gavi-supported low- and middle-income countries, 
2001–2020 and 2011–2020
2011–2020
2001–2020
2011–2020
2001–2020
2011–2020
2001–2020
2011–2020
2001–2020
2011–2020
2001–2020
2011–2020
2001–2020
2011–2020
2001–2020
2011–2020
2001–2020
2011–2020
2001–2020
2011–2020
2001–2020
JE
HPV
Rubella
NmA
Rotavirus
YF
Sp
HepB
Hib
Measles
Costs averted (billions of 2010 US$)
Productivity loss as the result of death
Transportation
Productivity loss as the result of disability
Treatment
Caregiver wages
0
50
100
150
HepB: hepatitis B virus; Hib: Haemophilus influenzae type b; HPV: human papillomavirus; JE: Japanese encephalitis virus; NmA: Neisseria meningitidis serogroup A; 
Sp: Streptococcus pneumoniae; US$: United States dollars; YF: yellow fever virus.
Fig. 2. Economic and social value gained, averted costs of illness and deaths averted annually, as the result of vaccinations against 10 
diseases, 73 Gavi-supported low- and middle-income countries, 2001–2020
Value gained and averted costs (billions of 2010 US$)
100
90
80
70
60
50
40
30
20
10
0
Thousands of deaths averted
2000
1800
1600
1400
1200
1000
800
600
400
200
0
Year
Economic and social value gained
Averted costs of illness
Deaths averted
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
US$: United States dollars.
 Bull World Health Organ 2017;95:629–638| doi: http://dx.doi.org/10.2471/BLT.16.178475
635
Research
Economic impact of vaccination against 10 diseases
Sachiko Ozawa et al.
as a result of the vaccinations we inves-
tigated – each of our Gavi-supported 
study countries could expect to avoid a 
mean of approximately US$ 5 million in 
treatment costs per year.
Most of the economic benefits of the 
vaccines we investigated come – or are 
expected to come –from the long-term 
gains associated with a more produc-
tive workforce. Our examination of the 
broader economic and social value of 
such vaccines, beyond labour produc-
tivity, illustrates the substantial gains 
associated with vaccination, with the 
value for all 73 study countries estimated 
to reach US$ 820 billion over the 20 
years since Gavi was launched in 2001. 
Unlike the lower estimates of the averted 
costs of treatment, our estimates of the 
broader economic and social value of 
vaccines reflect the non-economic value 
that people place on living longer and 
healthier lives.25,33 Sensitivity analyses 
indicate that future economic analyses 
on this topic could be made stronger by 
the collection of additional empirical 
data on disease burden.
Our main findings are similar to 
those of previous analyses of the health 
and economic impact of vaccinations. 
Using newer inputs for the health im-
pact models developed in 2013,6 our 
estimates are based on updated data on 
immunization coverages and disease 
burden and a newer version of Gavi’s 
strategic demand forecast.7 We also ex-
cluded the impact of a routine first-dose 
of measles vaccination and used a differ-
ent model to estimate the health impact 
of yellow fever vaccination. Whenever 
several different estimates of health im-
pact were available from multiple mod-
els – as was the case for H. influenzae 
type b, human papillomavirus, rotavirus 
and S. pneumoniae – we incorporated 
ranges for the impact in our sensitivity 
analyses. A previous estimate of the 
number of deaths expected to be averted 
between 2011 and 2020 in our study 
countries as the result of vaccinations 
against the same 10 diseases – i.e. 13 
million6 – is similar to our estimate, of 14 
million, taking into account the various 
updates that we made across models.
While the method we followed to 
estimate the averted costs of illness was 
similar to that used in previous analy-
ses,34 our analyses included an exten-
sion, upgrading and/or improvement 
of the diseases covered, health impact 
inputs, vaccine demand forecasts and 
data sources. The method we followed 
to produce our broader estimates of 
the economic and social value of vac-
cinations improves on earlier research35 
by using the annual per-capita value 
of an increase in life expectancy and 
also by capturing the value of life lived 
in disability. Our estimates of annual 
treatment costs for specific diseases are 
similar to those of previous related 
cost–effectiveness studies. For example, 
the annual treatment and societal 
costs averted due to introduction of 
rotavirus vaccine in low- and middle-
income countries were estimated to total 
US$ 440 million36 – when expressed in 
2010 US$ – compared with our corre-
sponding estimate of US$ 690 million.
Our analysis had several limita-
tions. Because of a lack of relevant 
input data across countries and years, 
many health impact models are static, 
have limited country-level empirical 
data for some inputs and do not include 
long-term effects such as herd immunity. 
Given the current downward trend in 
child mortality and in the proportion 
of childhood deaths attributable to 
vaccine-preventable diseases, estimates 
of the projected, future, health and 
economic impact of vaccinations may 
be overestimates. Furthermore, work 
is currently underway to refine and 
improve health impact models by the 
inclusion of probabilistic uncertainty 
analysis and programmatic constraints 
such as delayed vaccination, partial 
dosing and relative coverage – i.e. the 
extent to which deaths may be clustered 
in unvaccinated groups. Our analysis 
did not include health-system contribu-
tions or any other costs of vaccination 
programmes.37
Our results are likely to have been 
influenced by the underlying disease 
burden, the duration of time between 
vaccination and the vaccine-preventable 
disease, the size of the eligible birth 
cohorts, immunization coverage rates 
and the effectiveness of vaccination 
programmes. In general, vaccination 
programmes based on highly effica-
cious vaccines that are given in early 
childhood and target pathogens caus-
ing acute disease would be expected to 
have relatively high economic benefits. 
Vaccines administered later in life that 
target chronic infections occurring at 
older ages – e.g. vaccines against human 
papillomavirus – would be expected to 
have less economic benefit. Data from 
the vaccination programmes of coun-
tries with large populations, high disease 
burdens and considerable economic 
output contributed disproportionately 
to our global estimates. We did not es-
timate treatment costs for long-term 
disability because there were no relevant 
data for many of our study countries. We 
also did not capture the impact made 
by the vaccines included in the original 
Expanded Programme on Immuniza-
tion – e.g. the bacille Calmette–Guérin, 
diphtheria–tetanus–pertussis and polio 
vaccines and first doses of measles vac-
cine. In estimating the economic impact, 
we did not capture macroeconomic 
benefits – e.g. growth in gross domestic 
product – or the economic implications 
of demographic changes resulting from 
vaccination.38–40 In addition, empirical 
data on the value of a life-year are not 
available from interventions targeting 
children in low- and middle-income 
countries.
Despite these limitations, our re-
sults should give global decision-makers 
some idea of the full economic and 
social benefits that could be gained by 
increasing investments in immuniza-
tions. They have already informed 
Gavi’s investment strategy for the period 
2016–2020 and highlighted the need for 
better global-level estimates of the eco-
nomic impact of vaccination.41 Unlike 
the conservative estimates used in Gavi’s 
strategy, which incorporated additional 
uncertainty in the base parameters, our 
results were based on available coverage 
estimates and model outputs. It seems 
clear that, in averting substantial costs 
and potentially increasing economic 
productivity among the world’s poorest 
countries, the impact of immunization 
goes well beyond health. ■
Acknowledgements
We thank Gavin Grant, Emilia Vyn-
nycky, Susan Reef, Wenfeng Gong, 
Julie Buss Younkin, Diane Coraggio and 
Grace Morgan. AS is now an employee of 
the Center for Outcomes and Real-world 
Evidence, Merck & Co., Rahway, USA.
Funding: This study was performed with 
financial support from the Bill & Melinda 
Gates Foundation. 
Competing interests: None declared.
 Bull World Health Organ 2017;95:629–638| doi: http://dx.doi.org/10.2471/BLT.16.178475
636
Research
Economic impact of vaccination against 10 diseases
Sachiko Ozawa et al.
صخلم
 ةترفلا في لخدلا ةطسوتمو ةضفخنم نادلبلا نم اًدلب 73 في عينمتلا تايلمعل رّدقُلما يداصتقلاا رثلأا
2020و 2001 يماع ينب ام
 ةلوذبلما دوهلجا للاخ نم لمتحلما يداصتقلاا رثلأا ريدقت ضرغلا
 ةترفلا في تاحاقللاب اهنم ةياقولا نكمي ضارمأ 10 دض عينمتلل
 ةضفخنم نادلبلا نم اًدلب 73 في 2020و 2001 يماع ينب ام
 بناج نم قاطنلا عساو ًمعد ىقلتت يتلا لخدلا ةطسوتمو
.لاصملأا جاتنلإ )Gavi( ينصحتلاو تاحاقلل يلماعلا فلاحتلا
 يداصتقلاا رثلأا ريدقتل يحصلا رثلأا جذمن انمدختسا ةقيرطلا
 عونلا نم ةيلزنلا ةيمدتسلما دض عينمتلل ةعقوتلما ةيطغتلا قيقحتل
 يميللحا مرولا سويرفو ،)ب( دبكلا باهتلا سويرفو ،)ب(
 ةيلصلما ةرمزلاو ،ةبصلحاو ،نيابايلا غامدلا باهتلاو ،يشربلا
 ،ةينالملأا ةبصلحاو ،ليجعلا سويرفلاو ،)أ( ةيئاحسلا ةيسرينلا
 ،عينمتلا مدع عم ةنراقلمابو .ءارفصلا ىملحاو ،ةيوئرلا ةيدقعلاو
 رلاودلاب 2010 ماع في ةبستحلما – فيلاكتلل جذومن عضوب انمق
 رئاسخو لقنلا فيلاكتو ايهدافت مت يتلا ةلجاعملل – يكيرملأا
 زجعلا ببسب ةيجاتنلإا رئاسخو ةياعرلا يمدقم ىدل ةيجاتنلإا
 ريدقتل رمعلا ساسأ لىع مييقتلا ةقيرط انمدختسا دقو .ةافولاو
 في ،لوطأ ةترفل شيعلل عسولأا ةيعمتجلااو ةيداصتقلاا ةميقلا
.عينمتلا لىع لوصحلل ةجيتن ،لضفأ ةحص
 ام ةترفلا في ةحونملما تاحاقللا نأ لىإ انتاريدقت يرشت جئاتنلا
 نم رثكأ يدافت لىإ اًدلب 73 في يدؤتس 2020و 2001 يماع ينب
 .ضرلما فيلاكت نم رلاود رايلم 350 يرفوتو ةافو ةلاح نويلم 20
 تاحاقللاب اهعينتم مت يتلا زجعلاو تايفولا تلااح يدؤتسو
 ةايلحا ىدم رمتست ةيجاتنإ بساكم قيقتح لىإ نيدقعلا للاخ
 لىع يكيرمأ رلاود تارايلم 9و يكيرمأ رلاود رايلم 330 لياجمإب
 تايلمع سفن نإف ،ةحقللما تاعومجلما رمع ىدم لىعو .لياوتلا
 .جلاعلا فيلاكت في رلاود تارايلم 5 ـب ردقي ام رفوتس عينمتلا
 تاحاقللا هذله عسولأا ةيعمتجلااو ةيداصتقلاا ةميقلا ردقُتو
.يكيرمأ رلاود رايلم 820 غلبمب
 ةدايز لمتحاو ةظهابلا فيلاكتلا عنم للاخ نم جاتنتسلاا
 عينمتلا رثأ نإف ،لماعلا نادلب رقفأ ضعب ينب ةيداصتقلاا ةيجاتنلإا
.ةيحص عفانم قيقتح درمج ىطختي
摘要
2001-2020 年 73 个中低收入国家疫苗接种的预计经济影响
目的 评估 2001 到 2020 年间 73 个中低收入国家通过
针对 10 种疫苗可预防疾病进行疫苗接种可能实现的
经济影响。评估主要由全球疫苗联盟 (Gavi) 提供支持。
方法 我们使用健康影响模型评估了实现预期的乙型流
感嗜血杆菌、乙型肝炎、人乳头瘤病毒、乙型脑炎、
麻疹、A 群脑膜炎奈瑟菌、轮状病毒、风疹、肺炎双
球菌和黄热病疫苗接种覆盖率的经济影响。 与不进行
疫苗接种相比 , 我们以 2010 年的美元 (US$) 为单位建
立了成本模型——包括避免治疗节省的成本、运输成
本、护理人员的生产力损失和因残疾和死亡造成的生
产力损失。 我们使用“年生命值”方法估算了因免疫
接种而延长生命和保持更健康的生活的更广泛经济和
社会价值。
结果 我们估计 2001 年到 2020 年间 ,73 个国家的疫苗
接种将避免超过 2000 万人的死亡数和节省 3500 亿美
元的疾病成本。 二十年间通过疫苗接种避免的死亡和
残疾数预计将分别带来总额为 3300 亿美元和 90 亿美
元的终身生产力收益。 在接种疫苗人群的一生中接种
同种疫苗预计会节省 50 亿的治疗成本。 预计此类疫
苗接种的更广泛经济和社会价值达 8200 亿美元。
结论 通过减少世界上一些最贫穷国家的重大开支和提
高潜在的经济生产力 , 免疫接种的影响远不止在卫生
领域。
Résumé
Estimation de l’impact économique de la vaccination dans 73 pays à revenu faible et intermédiaire entre 2001 et 2020
Objectif Estimer l’impact économique qui pourrait découler des efforts 
de vaccination contre 10 maladies à prévention vaccinale déployés 
entre 2001 et 2020 dans 73 pays à revenu faible et intermédiaire, et 
largement soutenus par Gavi, l’Alliance du Vaccin.
Méthodes Nous avons utilisé des modèles d’évaluation de l’impact sur 
la santé pour estimer l’impact économique qui découlerait, si le taux 
de couverture prévu est atteint, des vaccinations contre Haemophilus 
influenzae type B, l’hépatite B, le papillomavirus humain, l’encéphalite 
japonaise, la rougeole, Neisseria meningitidis sérogroupe A, le rotavirus, 
la rubéole, Streptococcus pneumoniae et la fièvre jaune. Pour établir une 
comparaison avec l’absence de vaccination, nous avons modélisé les 
coûts – exprimés en dollars des États-Unis 2010 (USD) – des traitements 
évités, les coûts de transport, les pertes de productivité des soignants 
non professionnels et les pertes de productivité pour cause d’invalidité 
ou de décès. Nous avons utilisé une méthode permettant d’évaluer 
la valeur d’une année de vie pour estimer la valeur économique et 
sociale au sens large d’une vie plus longue et en meilleure santé grâce 
à la vaccination.
Résultats D’après nos estimations, les vaccinations pratiquées 
entre 2001 et 2020 dans les 73 pays permettront d’éviter plus de 
20 millions de décès et d’économiser 350 milliards de dollars des États-
Unis en coûts sanitaires. Les cas de décès et d’invalidité évités grâce à 
la vaccination pratiquée au cours de ces deux décennies entraîneront 
des gains de productivité permanents respectivement estimés à 
330 milliards de dollars des États-Unis et 9 milliards de dollars des 
États-Unis. On estime qu’au cours de la vie des cohortes vaccinées, les 
mêmes vaccinations permettront d’économiser 5 milliards de dollars 
des États-Unis en coûts de traitement. La valeur économique et sociale 
au sens large de ces vaccinations est estimée à 820 milliards de dollars 
des États-Unis.
Conclusion L’impact de la vaccination dépasse le domaine de la santé, 
car il permet d’éviter d’importants coûts et une augmentation potentielle 
de la productivité économique de certains des pays les plus pauvres 
du monde.
 Bull World Health Organ 2017;95:629–638| doi: http://dx.doi.org/10.2471/BLT.16.178475
637
Research
Economic impact of vaccination against 10 diseases
Sachiko Ozawa et al.
Резюме
Предположительные экономические последствия вакцинации в 73 странах с низким и средним 
уровнем дохода, 2001–2020 гг.
Цель Оценить экономические последствия, которые могут быть 
достигнуты благодаря усилиям в области вакцинации против 
10 предупреждаемых вакцинацией болезней, в период с 2001 по 
2020 г. в 73 странах с низким и средним уровнем дохода, которые 
в значительной степени поддерживаются ГАВИ (Глобальным 
альянсом по вакцинам и иммунизации).
Методы Мы использовали модели воздействия на здоровье 
для оценки экономических последствий достижения 
прогнозируемых покрытий вакцинацией против таких 
возбудителей инфекций, как Haemophilus influenzae типа b, 
вирус гепатита B, вирус папилломы человека, вирус японского 
энцефалита, вирус кори, Neisseria meningitidis серогруппы A, 
ротавирус, вирус краснухи, Streptococcus pneumoniae и вирус 
желтой лихорадки. При сравнении с отсутствием вакцинации 
мы моделировали затраты, выраженные в долларах США (US $) 
по курсу 2010 года: предотвращение расходов на лечение, 
транспортных расходов, нетрудоспособности лиц, ухаживающих 
за детьми, и нетрудоспособности из-за инвалидности и смерти. 
Мы использовали метод, основанный на ценности одного 
года жизни, чтобы оценить более широкую экономическую и 
социальную ценность более долгой жизни и лучшего состояния 
здоровья, достигнутых в результате иммунизации.
Результаты Мы подсчитали, что в 73 странах вакцинации, 
проведенные в период с 2001 по 2020 г., предотвратят более 
20 миллионов смертей и позволят сэкономить 350 миллиардов 
долларов США на затратах, связанных с болезнями. Смертность 
и инвалидность, предотвращенные с помощью вакцинации, 
проведенной в течение двух десятилетий, приведут к 
ожидаемому росту производительности труда на протяжении 
всей жизни на общую сумму 330 миллиардов долларов США и 
9 миллиардов долларов США соответственно. В течение жизни 
вакцинированных когорт те же вакцинации позволят сэкономить 
приблизительно 5 миллиардов долларов США на расходах на 
лечение. Более широкая экономическая и социальная ценность 
этих вакцинаций оценивается в 820 миллиардов долларов США.
Вывод Предотвращая значительные издержки и потенциально 
увеличивая экономическую производительность среди 
некоторых беднейших стран мира, влияние иммунизации выходит 
далеко за пределы здоровья.
Resumen
Impacto económico estimado de las vacunas en 73 países con ingresos bajos y medios, 2001-2020
Objetivo Estimar el impacto económico que probablemente se logaría 
con los esfuerzos de vacunar frente a 10 enfermedades evitables 
mediante la vacunación entre 2001 y 2020 en 73 países con ingresos 
bajos y medios ampliamente respaldados por la Gavi, la Vaccine Alliance.
Métodos Se utilizaron modelos de impacto sanitario para estimar el 
impacto económico de lograr las coberturas previstas de vacunación 
frente a Haemophilus influenzae tipo b, hepatitis B, virus del papiloma 
humano, encefalitis japonesa, sarampión, Neisseria meningitidis 
serogrupo A, rotavirus, rubéola, Streptococcus pneumoniae y fiebre 
amarilla. En comparación con la no vacunación, se modelaron los 
costes (expresados en dólares estadounidenses, USD, de 2010) de 
los tratamientos evitados, los costes de transporte, las pérdidas 
de productividad de los proveedores de salud y las pérdidas de 
productividad debido a la discapacidad y la muerte. Se utilizó el método 
de valor de vida anual para estimar de forma más amplia el valor 
económico y social del hecho de vivir más, con una mejor salud, como 
resultado de la inmunización.
Resultados Se estimó que, en los 73 países, las vacunas suministradas 
entre 2001 y 2020 evitarán más de 20 millones de muertes y ahorrarán 
350 000 millones de USD en costes de enfermedades. Las muertes y las 
discapacidades evitadas gracias a las vacunas suministradas durante 
las dos décadas tendrán como resultado unas ganancias permanentes 
estimadas en la productividad de un total de 330 000 millones de USD y 
9 000 millones de USD, respectivamente. Durante la vida de las cohortes 
vacunadas, se estima que las mismas vacunaciones ahorrarán 5 000 
millones de USD en costes de tratamientos. El valor económico y social 
más amplio de estas vacunas se estima en 820 000 millones de USD.
Conclusión El impacto de las vacunas es positivo más allá de la salud, 
ya que se evitan costes significativos y se aumenta potencialmente 
la productividad económica entre algunos de los países más pobres.
References
1. 
Brenzel L, Wolfson L, Fox-Rushby JA, Miller MA, Halsey N. Chapter 20: 
Vaccine-preventable diseases. In: Jamison DT, Breman JG, Measham AR, 
Alleyne G, Claeson M, Evans DB, et al., editors. Disease control priorities 
in developing countries. 2nd ed. Washington (DC): World Bank; 2006. pp. 
389–411. Available from: http://www.ncbi.nlm.nih.gov/books/NBK11768/ 
[cited 2017 Jun 5]. 
2. 
Ozawa S, Mirelman A, Stack ML, Walker DG, Levine OS. Cost-effectiveness 
and economic benefits of vaccines in low- and middle-income countries: 
a systematic review. Vaccine. 2012 Dec 17;31(1):96–108. doi: http://dx.doi.
org/10.1016/j.vaccine.2012.10.103 PMID: 23142307
3. 
Bärnighausen T, Bloom DE, Cafiero-Fonseca ET, O’Brien JC. Valuing 
vaccination. Proc Natl Acad Sci USA. 2014 Aug 26;111(34):12313–9. doi: 
http://dx.doi.org/10.1073/pnas.1400475111 PMID: 25136129
4. 
Bloom DE, Madhavan G. Vaccines: from valuation to resource allocation. 
Vaccine. 2015 Jun 8;33 Suppl 2:B52–4. doi: http://dx.doi.org/10.1016/j.
vaccine.2015.02.071 PMID: 26022569
5. 
Ozawa S, Clark S, Portnoy A, Grewal S, Brenzel L, Walker DG. Return on 
investment from childhood immunization in low- and middle-income 
countries, 2011-20. Health Aff (Millwood). 2016 Feb;35(2):199–207. doi: 
http://dx.doi.org/10.1377/hlthaff.2015.1086 PMID: 26858370
6. 
Lee LA, Franzel L, Atwell J, Datta SD, Friberg IK, Goldie SJ, et al. The 
estimated mortality impact of vaccinations forecast to be administered 
during 2011-2020 in 73 countries supported by the GAVI Alliance. 
Vaccine. 2013 Apr 18;31 Suppl 2:B61–72. doi: http://dx.doi.org/10.1016/j.
vaccine.2012.11.035 PMID: 23598494
7. 
Ozawa S, Clark S, Portnoy A, Grewal S, Stack M, Sinha A, et al. Methodologies 
to estimate the health and economic impact of vaccination against 10 
vaccine-preventable diseases. Baltimore: Johns Hopkins Bloomberg School 
of Public Health; 2016.
8. 
WHO/UNICEF Estimates of National Immunization Coverage (WUENIC). 
Geneva: World Health Organization; 2016. Available from: http://www.who.
int/immunization/monitoring_surveillance/data/en/ [cited 2016 May 27].
9. 
The 2016-2017 investment opportunity. Geneva: Gavi, the Vaccine 
Alliance; 2015. Available from: http://www.gavi.org/library/publications/
publications-gavi/the-2016-2020-gavi-alliance-investment-opportunity/ 
[cited 2016 May 27].
 Bull World Health Organ 2017;95:629–638| doi: http://dx.doi.org/10.2471/BLT.16.178475
638
Research
Economic impact of vaccination against 10 diseases
Sachiko Ozawa et al.
10. Hodgson TA. Costs of illness in cost-effectiveness analysis. A review of the 
methodology. Pharmacoeconomics. 1994 Dec;6(6):536–52. doi: http://
dx.doi.org/10.2165/00019053-199406060-00007 PMID: 10155283
11. WHO guide to identifying the economic consequences of disease and 
injury. Geneva: World Health Organization; 2009.
12. The state of the world’s children 2013: children with disabilities. New York: 
United Nations Children’s Fund; 2013. Available from: https://www.unicef.
org/sowc2013/files/SWCR2013_ENG_Lo_res_24_Apr_2013.pdf [cited 2017 
Jun 5].
13. Bishai D, Johns B, Nair D, Nabyonga-Orem J, Fiona-Makmot B, Simons E, 
et al. The cost-effectiveness of supplementary immunization activities for 
measles: a stochastic model for Uganda. J Infect Dis. 2011 Jul;204 Suppl 
1:S107–15. doi: http://dx.doi.org/10.1093/infdis/jir131 PMID: 21666151
14. Kim SY, Lee G, Goldie SJ. Economic evaluation of pneumococcal conjugate 
vaccination in The Gambia. BMC Infect Dis. 2010 09 3;10(1):260. doi: http://
dx.doi.org/10.1186/1471-2334-10-260 PMID: 20815900
15. Lee BY, Connor DL, Kitchen SB, Bacon KM, Shah M, Brown ST, et al. 
Economic value of dengue vaccine in Thailand. Am J Trop Med Hyg. 2011 
May;84(5):764–72. doi: http://dx.doi.org/10.4269/ajtmh.2011.10-0624 
PMID: 21540387
16. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness 
and deaths caused by rotavirus disease in children. Emerg Infect Dis. 2003 
May;9(5):565–72. doi: http://dx.doi.org/10.3201/eid0905.020562 PMID: 
12737740
17. Rudan I, Tomaskovic L, Boschi-Pinto C, Campbell H; WHO Child Health 
Epidemiology Reference Group. Global estimate of the incidence of clinical 
pneumonia among children under five years of age. Bull World Health 
Organ. 2004 Dec;82(12):895–903. PMID: 15654403
18. Sinha A, Constenla D, Valencia JE, O’Loughlin R, Gomez E, de la Hoz F, 
et al. Cost-effectiveness of pneumococcal conjugate vaccination in 
Latin America and the Caribbean: a regional analysis. Rev Panam Salud 
Publica. 2008 Nov;24(5):304–13. doi: http://dx.doi.org/10.1590/S1020-
49892008001100002 PMID: 19141172
19. Cost effectiveness and strategic planning (WHO-CHOICE) [Internet]. 
Geneva: World Health Organization; 2008. Available from: http://www.who.
int/choice/costs/en/ [cited 2016 May 27].
20. Kim SY, Sweet S, Slichter D, Goldie SJ. Health and economic impact of 
rotavirus vaccination in GAVI-eligible countries. BMC Public Health. 2010 
05 14;10(1):253. doi: http://dx.doi.org/10.1186/1471-2458-10-253 PMID: 
20470426
21. Country reports on human rights practices for 2012 [Internet]. Washington 
(DC): United States Department of State; 2012. Available from: http://www.
state.gov/j/drl/rls/hrrpt/humanrightsreport/index.htm [cited 2014 Jan 6].
22. The world population prospects: 2012 revision: life expectancy at exact 
age - both sexes [Internet]. New York: United Nations; 2012. Available from: 
https://esa.un.org/unpd/wpp/publications/Files/WPP2012_HIGHLIGHTS.
pdf [cited 2014 Jan 6].
23. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. 
Common values in assessing health outcomes from disease and injury: 
disability weights measurement study for the Global Burden of Disease 
Study 2010. Lancet. 2012 Dec 15;380(9859):2129–43. doi: http://dx.doi.
org/10.1016/S0140-6736(12)61680-8 PMID: 23245605
24. Download entire World Economic Outlook database [Internet]. Washington 
(DC): International Monetary Fund; 2013. Available from: http://www.imf.
org/external/pubs/ft/weo/2013/01/weodata/download.aspx [cited 2014 
Jan 6].
25. Alberini A. What is a life worth? Robustness of VSL values from contingent 
valuation surveys. Risk Anal. 2005 Aug;25(4):783–800. doi: http://dx.doi.
org/10.1111/j.1539-6924.2005.00646.x PMID: 16268929
26. Klose T. The contingent valuation method in health care. Health Policy. 1999 
May;47(2):97–123. doi: http://dx.doi.org/10.1016/S0168-8510(99)00010-X 
PMID: 10538292
27. Jamison DT, Summers LH, Alleyne G, Arrow KJ, Berkley S, Binagwaho A, 
et al. Global health 2035: a world converging within a generation. Lancet. 
2013 Dec 7;382(9908):1898–955. doi: http://dx.doi.org/10.1016/S0140-
6736(13)62105-4 PMID: 24309475
28. Stenberg K, Axelson H, Sheehan P, Anderson I, Gülmezoglu AM, 
Temmerman M, et al.; Study Group for the Global Investment Framework for 
Women’s Children’s Health. Advancing social and economic development 
by investing in women’s and children’s health: a new Global Investment 
Framework. Lancet. 2014 Apr 12;383(9925):1333–54. doi: http://dx.doi.
org/10.1016/S0140-6736(13)62231-X PMID: 24263249
29. Viscusi WK, Aldy JE. The value of a statistical life: a critical review of market 
estimates throughout the world. J Risk Uncertain. 2003;27(1):5–76. doi: 
http://dx.doi.org/10.1023/A:1025598106257
30. Cropper M, Hammitt JK, Robinson L. Valuing mortality risk reductions: 
progress and challenges. Annu Rev Resour Economics. 2011;3(1):313–36. 
doi: http://dx.doi.org/10.1146/annurev.resource.012809.103949
31. Hammitt JK, Robinson LA. The income elasticity of the value per statistical 
life: transferring estimates between high and low income populations. J 
Benefit Cost Anal. 2011;2(1). doi: http://dx.doi.org/10.2202/2152-2812.1009
32. Pearce D. Valuing risks to life and health: towards consistent transfer 
estimates in the European Union and Accession States. Brussels: European 
Commission; 2000. Available from: http://ec.europa.eu/environment/
enveco/others/pdf/david_pearce_paper.pdf [cited 2017 Jun 5].
33. Ashenfelter O. Measuring the value of a statistical life: problems and 
prospects. Cambridge: National Bureau of Economic Research; 2006. doi: 
http://dx.doi.org/10.3386/w11916
34. Stack ML, Ozawa S, Bishai DM, Mirelman A, Tam Y, Niessen L, et al. 
Estimated economic benefits during the ‘decade of vaccines’ include 
treatment savings, gains in labor productivity. Health Aff (Millwood). 2011 
Jun;30(6):1021–8. doi: http://dx.doi.org/10.1377/hlthaff.2011.0382 PMID: 
21653952
35. Ozawa S, Stack ML, Bishai DM, Mirelman A, Friberg IK, Niessen L, et al. 
During the ‘decade of vaccines,’ the lives of 6.4 million children valued at 
$231 billion could be saved. Health Aff (Millwood). 2011 Jun;30(6):1010–20. 
doi: http://dx.doi.org/10.1377/hlthaff.2011.0381 PMID: 21653951
36. Rheingans RD, Antil L, Dreibelbis R, Podewils LJ, Bresee JS, Parashar UD. 
Economic costs of rotavirus gastroenteritis and cost-effectiveness of 
vaccination in developing countries. J Infect Dis. 2009 Nov 1;200(s1) Suppl 
1:S16–27. doi: http://dx.doi.org/10.1086/605026 PMID: 19817595
37. Portnoy A, Ozawa S, Grewal S, Norman BA, Rajgopal J, Gorham KM, et al. 
Costs of vaccine programs across 94 low- and middle-income countries. 
Vaccine. 2015 May 7;33 Suppl 1:A99–108. doi: http://dx.doi.org/10.1016/j.
vaccine.2014.12.037 PMID: 25919184
38. Bärnighausen T, Berkley S, Bhutta ZA, Bishai DM, Black MM, Bloom 
DE, et al. Reassessing the value of vaccines. Lancet Glob Health. 2014 
May;2(5):e251–2. doi: http://dx.doi.org/10.1016/S2214-109X(13)70170-0 
PMID: 25103158
39. Jit M, Hutubessy R, Png ME, Sundaram N, Audimulam J, Salim S, et al. The 
broader economic impact of vaccination: reviewing and appraising the 
strength of evidence. BMC Med. 2015 09 3;13(1):209. doi: http://dx.doi.
org/10.1186/s12916-015-0446-9 PMID: 26335923
40. Schwartz JL, Mahmoud A. When not all that counts can be counted: 
economic evaluations and the value of vaccination. Health Aff (Millwood). 
2016 Feb;35(2):208–11. doi: http://dx.doi.org/10.1377/hlthaff.2015.1438 
PMID: 26858371
41. Ozawa S, Grewal S, Portnoy A, Sinha A, Arilotta R, Stack ML, et al. Funding 
gap for immunization across 94 low- and middle-income countries. 
Vaccine. 2016 Dec 7;34(50):6408–16. doi: http://dx.doi.org/10.1016/j.
vaccine.2016.09.036 PMID: 28029541
